Joseph Ciccolini

Ful Professor

Aix-Marseille University

France

Research Interests

Explore related searches

Professors in France Professors in Cancer Biology Cancer Biology professors in France

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Joseph Ciccolini is a Ful Professor at Aix-Marseille University in France. His research focuses on pharmacokinetics, drug dosing regimens in oncology, and the evaluation of therapeutic efficacy of various cancer treatments. Recent articles by Professor Ciccolini explore topics such as alternative dosing strategies for immune checkpoint inhibitors, the impact of genetic factors on chemotherapy outcomes, and the pharmacodynamics of targeted therapies in cancer patients.

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Collaborators (6)

Anne Rodallec

Assistant professor

Aix-Marseille Université

FRANCE

View details

LUCA MORELLI

Professore Associato in Chirurgia Generale

University of Pisa

ITALY

View details

Nicolas Pallet

Université Paris Cité

FRANCE

View details

Laurent Chouchana

FRANCE

View details

Benoit Blanchet

FRANCE

View details

Palma Rocchi

FRANCE

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Joseph Ciccolini

Research Interests

Explore related searches

Contact this professor

About

Articles (20)

Eco Friendly and Budget Smart: An Economic and Environmental Evaluation of Alternative PD-1 and PD-L1 Inhibitor Dosing Regimens

DPD Ultra‐Rapid Metabolizer Status and Efficacy of 5‐Fluorouracil Treatment: A Real‐World Study

Adaptive dosing of high‐dose busulfan in real‐world adult patients undergoing haematopoietic cell transplant conditioning

A Big Problem With a Feasible Solution, Not a Small Problem With a Complex Solution

Body mass index affects imatinib exposure: Real‐world evidence from TDM with adaptive dosing

Large-Scale DPD Testing Should Be More Than an Option

Life-threatening toxicities upon Pembrolizumab intake: could pharmacokinetics be the bad guy?

Overcoming immuno-resistance by rescheduling anti-VEGF/cytotoxics/anti-PD-1 combination in lung cancer model

Current diagnostic and clinical issues of screening for dihydropyrimidine dehydrogenase deficiency

Killing a fly with a sledgehammer: Atezolizumab exposure in real‐world lung cancer patients

The CetuxIMAX protocol: a non-interventional, uncontrolled, and non-comparative multicentric study for exploring the pharmacokinetics/pharmacodynamics relationships of cetuximab in head and neck cancer patients

Machine-Learning Exploration of Exposure-Effect Relationships of Cisplatin in Head and Neck Cancer Patients

Renal impairment and DPD testing: Watch out for false‐positive results!

Adaptive dosing of sunitinib in a metastatic renal cell carcinoma patient: when in silico modeling helps to go quicker to the point

Potential Role of Exosomes in the Chemoresistance to Gemcitabine and Nab-Paclitaxel in Pancreatic Cancer

Cross-Validation of a Multiplex LC-MS/MS Method for Assaying mAbs Plasma Levels in Patients with Cancer: A GPCO-UNICANCER Study

Clinical-Based vs. Model-Based Adaptive Dosing Strategy: Retrospective Comparison in Real-World mRCC Patients Treated with Sunitinib

Detecting DPD deficiency: when perfect is the enemy of good

The association between adverse events and outcome under checkpoint inhibitors: Where is the deal?

Enhanced Antisense Oligonucleotide Delivery Using Cationic Liposomes Grafted with Trastuzumab: A Proof-of-Concept Study in Prostate Cancer

Collaborators (6)

Anne Rodallec

LUCA MORELLI

Nicolas Pallet

Laurent Chouchana

Benoit Blanchet

Palma Rocchi

Make your next move.